GSK plc (NYSE:GSK) Shares Purchased by Stablepoint Partners LLC

Stablepoint Partners LLC raised its holdings in shares of GSK plc (NYSE:GSK - Free Report) by 21.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,796 shares of the pharmaceutical company's stock after buying an additional 21,232 shares during the period. Stablepoint Partners LLC's holdings in GSK were worth $4,680,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in GSK. FMR LLC raised its stake in shares of GSK by 82.1% during the fourth quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock valued at $1,786,475,000 after purchasing an additional 23,814,104 shares during the period. Primecap Management Co. CA raised its stake in shares of GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock valued at $854,349,000 after purchasing an additional 10,407,905 shares during the period. Voloridge Investment Management LLC raised its stake in shares of GSK by 1,360.4% during the fourth quarter. Voloridge Investment Management LLC now owns 2,165,043 shares of the pharmaceutical company's stock valued at $73,222,000 after purchasing an additional 2,016,795 shares during the period. Bridgewater Associates LP raised its stake in shares of GSK by 132.7% during the fourth quarter. Bridgewater Associates LP now owns 2,247,691 shares of the pharmaceutical company's stock valued at $76,017,000 after purchasing an additional 1,281,855 shares during the period. Finally, Woodline Partners LP bought a new stake in shares of GSK in the fourth quarter worth $36,665,000. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Performance

GSK stock opened at $41.11 on Friday. The company has a market capitalization of $84.82 billion, a P/E ratio of 25.86, a PEG ratio of 1.12 and a beta of 0.51. The company has a 50-day simple moving average of $37.53 and a 200 day simple moving average of $36.34. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $44.67. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.08 by $0.05. The company had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. The business's revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS. Sell-side analysts predict that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Investors of record on Friday, May 16th will be issued a dividend of $0.4216 per share. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a dividend yield of 4.10%. The ex-dividend date of this dividend is Friday, May 16th. GSK's dividend payout ratio (DPR) is currently 86.60%.

Analyst Ratings Changes

A number of brokerages recently issued reports on GSK. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a research note on Monday, April 28th. Morgan Stanley began coverage on shares of GSK in a research note on Wednesday, February 12th. They issued an "equal weight" rating for the company. Berenberg Bank restated a "hold" rating on shares of GSK in a research note on Tuesday. BNP Paribas began coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. Finally, Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $37.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.